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Simple Summary: Gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) are a family of
rare cancers with rising incidence in recent years. GEP NEN tumor cells are difficult to propagate,
and few cellular and patient-derived xenograft (PDX) models are available for testing new therapies
and studying the heterogeneous nature of these cancers. Here, we described the establishment and
characterization of two novel NEC cellular and PDX models (NEC913 and NEC1452). NEC913
PDX tumors express somatostatin receptor 2 (SSTR2), whereas NEC1452 PDX tumors are SSTR2
negative. As a proof-of-concept study, we demonstrated how these PDX models can be used for
peptide imaging experiments targeting SSTR2 using fluorescently labelled octreotide. The NEC913
and NEC1452 PDX lines represent valuable new tools for accelerating the process of drug discovery
for GEP NENs.
Abstract: Gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) are rare cancers consisting of neuroendocrine carcinomas (NECs) and neuroendocrine tumors (NETs), which have been
increasing in incidence in recent years. Few cell lines and pre-clinical models exist for studying
GEP NECs and NETs, limiting the ability to discover novel imaging and treatment modalities. To
address this gap, we isolated tumor cells from cryopreserved patient GEP NECs and NETs and
injected them into the flanks of immunocompromised mice to establish patient-derived xenograft
(PDX) models. Two of six mice developed tumors (NEC913 and NEC1452). Over 80% of NEC913
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and NEC1452 tumor cells stained positive for Ki67. NEC913 PDX tumors expressed neuroendocrine
markers such as chromogranin A (CgA), synaptophysin (SYP), and somatostatin receptor-2 (SSTR2),
whereas NEC1452 PDX tumors did not express SSTR2. Exome sequencing revealed loss of TP53
and RB1 in both NEC tumors. To demonstrate an application of these novel NEC PDX models
for SSTR2-targeted peptide imaging, the NEC913 and NEC1452 cells were bilaterally injected into
mice. Near infrared-labelled octreotide was administered and the fluorescent signal was specifically
observed for the NEC913 SSTR2 positive tumors. These 2 GEP NEC PDX models serve as a valuable
resource for GEP NEN therapy testing.
Keywords: gastroenteropancreatic neuroendocrine neoplasms; patient-derived xenograft; tumor
spheroids; somatostatin receptor-2; near infrared-labelled octreotide analog

1. Introduction
Tumors can arise within neuroendocrine cells throughout the body, and some of
the most common sites that lead to human morbidity and mortality originate within the
GI system, most commonly within the small bowel and pancreas, collectively known
as gastroenteropancreatic neuroendocrine neoplasms (GEP NENs). The age-adjusted
incidence of GEP NENs increased over sixfold in the United States between 1973 and
2012, with an annual incidence of 3.56 per 100,000 persons [1]. These tumors are typically
slow growing, but over 60% of patients present with metastatic disease and survival is
greatly diminished [2–4]. In addition to the stage of the disease, both tumor grade and cell
morphology/degree of differentiation are also powerful predictors of survival. Based on the
2019 World Health Organization classification of neuroendocrine neoplasms, GEP NENs are
comprised of well-differentiated neuroendocrine tumors (NETs) and poorly-differentiated
neuroendocrine carcinomas (NECs) [5]. Grade 1, 2, and 3 NETs are all morphologically
well-differentiated and have Ki-67 values of <3%, 3–20%, and >20%, respectively. NECs are
poorly differentiated tumors with a Ki-67 proliferation index >20% and/or a mitotic rate
of over 20 mitoses per 2 mm2 , and many NECs have Ki-67 indices >50% [5]. In addition
to these distinguishing features of poor differentiation and high Ki-67, GEP NECs have
frequent mutations in TP53 and RB1, while mutations in NET tumors are less common,
and include MEN1, DAXX, and ATRX for pancreatic NETs (PNETs) and CDKN1B and 18q
loss in small bowel NETs (SBNETs) [5–7].
Clinically, NECs are very aggressive, rapidly dividing tumors. They are associated
with high rates of metastatic disease at presentation and poor prognosis. The incidence
of NECs is not as well-defined due to changes in the WHO classification over the past
decade, but epidemiological studies estimate this to be about 0.4/100,000 person-years [1,8].
The optimal treatment for GEP NECs has not been established due in part to the rarity
of these tumors and difficulty with performing randomized trials. As a result, current
guidelines for treatment of GEP NEC are based on lower-level evidence (NCCN Guidelines
2021) [9]. Therapeutic strategies are largely derived from experience in management of
small cell lung cancer due to the pathologic and immunohistochemical similarities between
small cell lung cancer and GEP NECs [10–12]. The appropriateness of this has been
called into question as small cell lung cancer differs from NECs in several ways including
higher association with smoking, higher rate of brain metastases, and higher sensitivity to
platinum-based chemotherapy [11–14]. Patients are generally treated with chemotherapy
regimens including platinum-based alkylating agents (carboplatin) and topoisomerase
inhibitors (etoposide). Despite treatment, response rates are only 30–50% and median
overall survival is 9 to 20 months [13–15].
Current therapies for both NETs and NECs are limited to somatostatin analogues
(SSAs), mTOR inhibitors (everolimus), tyrosine kinase inhibitors (sunitinib), limited
chemotherapy regimens, and peptide receptor radionuclide therapy (PRRT) [16–18]. One
of the biggest barriers to identifying additional active therapeutics has been the inability
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to establish GEP NEN cell lines and mouse models that can be grown robustly. Some of
these tumor cells can be grown in culture as spheroids, but they grow very slowly and
are difficult to propagate as xenografts [19–21]. The two widely used cell lines, BON [22]
and QGP1 [23] resemble poorly differentiated NECs [24–26], and unfortunately express
low levels of NEN markers such as the somatostatin receptor 2 (SSTR2) [24]. Although
well-differentiated GEP NET cell lines, such as the P-STS, GOT1, and NT-3 cells, have
been described [24,25,27], difficulties growing these cells in abundance have limited their
distribution to other researchers. The paucity of available cell lines has been a significant
hurdle towards better understanding NEN biology and to provide theranostic models, and
therefore we set out to establish new models to expand these options for NEN research.
2. Methods
2.1. Patient-Derived Xenograft Models and Cell Lines
The inventory of the Washington University PDX center was searched for neuroendocrine tumors and carcinomas, which were collected under an Institutional Review
Board-approved protocol (#201708051) of Washington University and cryo-preserved. All
peripheral blood and patient tumor tissue were procured on the day of surgery. Peripheral
blood was layered onto a Ficoll gradient, peripheral blood mononuclear cells (PBMCs)
isolated, rinsed, 5 × 106 /mL transferred to cryovials, and cryopreserved in FBS + 10%
DMSO. Tumor tissues were kept cold, cut into multiple small pieces, 5 pieces transferred
into each cryovial, and cryopreserved in FBS + 10% DMSO. All cryopreserved samples
were progressively cooled in a freezing container at a controlled rate of −1 ◦ C/min at
−80 ◦ C. Vials were subsequently transferred to liquid nitrogen for long term storage.
Six patient samples were selected for this study. Tumors were thawed, minced, digested with collagenase and DNase I, and strained to obtain a single-cell suspension [19].
One to ten thousand cells were injected subcutaneously into NOD scid gamma (NSG) mice
under an Institutional Animal Care and Use Committee-approved protocol (#9051771).
Once visible subcutaneous tumors developed, tumor volume was calculated by multiplying
tumor length, width, and depth and expressed as mm3 . Tumors larger than 1000 mm3 were
harvested, processed, and 1 million tumor cells were injected into another generation of
NSG mice, and remaining cells were placed in suspension culture. After 2 days of incubation, mouse fibroblasts from the PDX tumors were easily removed since they adhered
to the plastic culture dish while the NEC cells grew in suspension. The floating NEC cells
were harvested and transferred into new culture dishes. After 3 passages, the cultures
consisted of only NEC cells with no fibroblast contamination was observed. NEC tumor
cells can also be seeded in extracellular matrix as 3-dimensional cultures. For optimal NET
marker expression, use NEC cells recently isolated from PDX tumors and avoid using cells
in culture over 6 months. NEC tumor cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM)/F12 with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin,
1% L-glutamine, insulin, and nicotinamide [19]. BON cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM)/F12 with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 1% L-glutamine [22].
2.2. Histology and Immunohistochemistry
Patient samples from surgery were fixed in formalin, embedded in paraffin, and
sectioned. Slides were deparaffinized, rehydrated, and stained with hematoxylin and
eosin (H&E). Slides were immunostained using specific antibodies against chromogranin A
(CgA) (Thermo Scientific, Waltham, MA, USA, #MA5-13096), synaptophysin (SYP) (Agilent
Dako, Santa Clara, CA, USA, #M7315), achaete-scute family bHLH transcription factor 1
(ASCL1) (BD Pharmingen, San Diego, CA, USA, #556604), p53 (Agilent Dako, #M700101-2),
retinoblastoma protein (Rb) (BD Pharmingen, #554136), somatostatin receptor 2 (SSTR2)
(Abcam, Waltham, MA, USA, #ab134152), and C-X-C motif chemokine receptor 4 (CXCR4)
(Abcam, #ab124824), and Ki-67 (Agilent Dako, #M724001-2). Ki-67 proliferation index was
quantified by percentage of positively staining cells in ~500 tumor cells per tumor sample.
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2.3. Quantitative PCR
RNA was extracted from tumors grown in mice using the RNeasy Plus Universal Kit
(Qiagen, Beverly, MA, USA) and reverse transcribed to cDNA using the qScript cDNA
Supermix (QuantaBio, Beverly, MA, USA). Quantitative PCR was performed with genespecific primers and PerfeCTa SYBR Green Supermix dye (Quantabio) using the 7900HT
Fast Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). Primer sequences
were obtained from PrimerBank (https://pga.mgh.harvard.edu/primerbank, accessed on
the 8 July 2020) and were purchased from Integrated DNA Technologies (IDT). Primer
sequences used for qPCR analysis are shown in Table 1.
Table 1. List of primer sequences used for qPCR experiments.
Gene Symbol

Forward

Reverse

GAPDH
CGA
SYP
SSTR1
SSTR2
SSTR3
SSTR4
SSTR5
CXCR4

GGAGCGAGATCCCTCCAAAAT
TAAAGGGGATACCGAGGTGATG
CTCGGCTTTGTGAAGGTGCT
GCGCCATCCTGATCTCTTTCA
TGGCTATCCATTCCATTTGACC
AGAACCTGAGAATGCCTCCTC
GCATGGTCGCTATCCAGTG
GTGATCCTTCGCTACGCCAA
ACGCCACCAACAGTCAGAG

GGCTGTTGTCATACTTCTCATGG
TCGGAGTGTCTCAAAACATTCC
CTGAGGTCACTCTCGGTCTTG
AACGTGGAGGTGACTAGGAAG
AGGACTGCATTGCTTGTCAGG
GCCGCAGGACCACATAGATG
GCGAAGGATCACGAAGATGAC
CACGGTGAGACAGAAGACGC
AGTCGGGAATAGTCAGCAGGA

2.4. Immunofluorescence
Cells derived from mouse tumors were fixed with 4% paraformaldehyde for 10 min,
then stained with primary antibodies against SYP (Abcam, #32127) at 1:600 dilution, CgA
(Invitrogen, Waltham, MA, USA, #MA5-13096) at 1:400 dilution, and SSTR2 (Sigma, St.
Louis, MO, USA, #HPA007264) at 1:400 dilution overnight. Cells were washed and incubated with an FITC-conjugated secondary antibody (Jackson ImmunoResearch, West Grove,
PA, USA, #115-095-062 and #711-095-152) at 1:500 dilution for 1 h. Immunofluorescent
images were taken using a fluorescent microscope at 200 ms exposure time.
2.5. Genomic DNA Analyses
Genomic DNA from PDX tumors, and peripheral blood mononuclear cells (PBMCs)
were extracted using a DNA extraction kit (Qiagen). Short tandem repeats (STR) analyses were performed on the DNA samples using the Cell Check9 panel of 9 human STR
polymorphisms (IDEXX, Westbrook, ME, USA). Exome sequencings of PDX tumors were
performed by submitting genomic DNA from NEC913 and NEC1452 PDX tumors to the
Washington University Genome Technology Access Center for analyses with the IDT Exome 150X coverage. Exome sequencing data were analyzed using a DRAGEN processor
and compared to the GRCh38 reference genome.
2.6. Imaging of Patient-Derived Xenograft Mouse Model with Bilateral Tumors
Five female NSG mice (Jackson Laboratory, Bar Harbor, ME, USA, Stock no: 005557)
were anesthetized with 1% to 2% isoflurane at 10 weeks of age, and were subcutaneously
injected with 1 × 106 SSTR2(+) cells in extracellular matrix Matrigel (Corning, Corning,
NY, USA, #356235) in the left shoulder, and 1 × 106 SSTR2(−) cells in the right shoulder.
When bilateral tumor size reached between 10 to 20 mm in diameter at 5 weeks postimplantation, in vivo and ex vivo near infrared (NIR) fluorescence imaging were conducted
with NIR octreotide analog (NIR-TOC) as described by Hernandez-Vargas et al. [28,29]
In brief, 6 nmol of NIR-TOC diluted in 100 µL PBS was administered via mouse tail-vein
injection 24 h prior to imaging studies. NIR fluorescence imaging was acquired using the
IVIS Lumina S5 small animal imaging station and Living Image® software (PerkinElmer,
Waltham, MA, USA) with excitation and emission set to 740 and 790 nm, respectively.
Images with favorable contrast-to-noise ratio were obtained using exposure time of 2 s for
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in vivo and 0.1 s for ex vivo imaging, with subject height of 1.50 cm, small binning and
F/Stop setting of 2, and field of view setting C. After completing in vivo imaging, mice
were euthanized and dissection was immediately performed for ex vivo isolation, and
imaging of subcutaneous tumors as well as major intraabdominal and intrathoracic organs
was performed. Quantification of NIR fluorescent signal was performed using ImageJ
version 1.53 a (NIH, Bethesda, MD, USA). Statistical analyses for NIR fluorescent signal
were performed using t-tests in Prism GraphPad. p < 0.05 was depicted with *.
3. Results
Tumor cells from six cryopreserved patient tumors (Table 2) were injected into the flank
of NSG mice to generate PDX models (Figure 1A). At 3 months post-tumor cell injection,
two mice harboring GEP NEC cells had developed subcutaneous tumors of approximately
1 cm in diameter (NEC913 and NEC1452; Figure 1A) while four GEP NET patient tumor
cell samples injected into mice did not form tumors (Table 2). Subcutaneous injection of
1 × 106 NEC913 and NEC1452 cells grew into tumors about 1000 mm3 and 1500 mm3 in size,
respectively, after 5 weeks in subsequent passages. The tumor formation rate was 100%. The
NEC913 and NEC1452 xenograft tumors were harvested and collected for histological and
biochemical analyses. A separate portion of the NEC913 and NEC1452 tumors was collected
for tumor cell isolation and injection into another generation of mice for propagation of
the PDX models and for establishment of cell lines. Both NEC913 and NEC1452 cells were
successfully maintained in culture for months in enriched DMEM/F12 medium. Both PDX
tumors stained positive for the neuroendocrine tumor markers chromogranin A (CgA) and
synaptophysin (SYP), but only the NEC913 PDX tumor stained positive for somatostatin
receptor 2 (SSTR2; Figure 1B). Exome sequencing of the NEC913 and NEC1452 PDX tumors
were performed and mutations in TP53 and RB1 were confirmed (Figure 1C; Supplementary
Tables S1 and S2).
Table 2. List of GEP NEN patient tumor samples used for patient-derived xenograft (PDX) development.
Patient Tumor
ID Number

Classification of
Tumor

WHO
Terminology

Differentiation

Tumor
Grade

Ki67 (%)

Establishment
of PDX

PNET459

Pancreatic NET

NET Grade 2

Well differentiated

Intermediate

7

no

PNET560

Pancreatic NET

NET Grade 2

Well differentiated

Intermediate

8.4

no

PNET1164

Pancreatic NET

NET Grade 2

Well differentiated

Intermediate

13

no

SBNET1063

Small bowel NET

NET Grade 3

Well differentiated

High

80

no

High

80–90

yes

High

80–90

yes

NEC913

Ampullary NEC

NEC, small and
large-cell types

Poorly
differentiated

NEC1452

Rectal NEC

NEC, large-cell type

Poorly
differentiated

We were able to retrieve the original patient tumor for the NEC913 sample for comparison with the PDX model. The NEC913 tumor came from a patient presenting with
jaundice and upper GI bleeding. A biopsy revealed a Grade 3 NEC of the ampulla of
Vater, and the patient was treated with carboplatin/etoposide chemotherapy for 4 months,
then had a Whipple procedure, where a 0.3 cm primary tumor with multiple involved
nodes were also removed (Figure 2A). Hematoxylin and eosin (H&E) staining showed
the presence of both small and large NEC cells (Figure 2B). The NEC913 primary tumor
stained positive for Ki-67 in over 80% of cells (Figure 2C). An outside pathology report
indicated that the specimen was TTF-1 positive and CDX2 negative. We detected positive
staining for CgA, SYP, SSTR2, and ASCL1 (Figure 2D–G). A low level of p53 was detected
(Figure 2H); however, exome sequencing data identified several stopgain mutations where
the first stopgain mutation is located in codon 147 of TP53 (Figure 1C, Supplementary
Table S1) suggesting that the IHC staining detect only the first 146 amino acid fragment of
p53. Expression of Rb was lost (Figure 2I). Exome sequencing of the NEC913 PDX tumor
revealed an RB1 frameshift insertion (1091_1092insCG) leading to a premature stop codon
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(Figure 1C, Supplementary Table S1). STR analyses confirmed that the NEC913 patient
blood sample shared the same alleles with the NEC913 PDX tumor (Supplementary Table
6 of 14
S3) and that these samples did not match any of the existing research samples in the IDEXX
DSMZ STR database, meaning that they are being reported for the first time.

A)
NEC913 PDX
NEC1452 PDX

4X

B)

No tumor
H&E
H&E

Ki67
Ki67

CgA
CgA

H&E

Ki67

CgA

SYP
Syn

SSTR2
SSTR2

SYP

SSTR2

NEC913 PDX

NEC1452 PDX

C)
NEC913 PDX
NEC1452 PDX

RB1
frameshift insertion
frameshift deletion

TP53
stopgain
stopgain

APC
stopgain

Figure
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patient-derived
xenograft
(PDX)
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xenograft
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els:
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and
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the
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Scid Gamma
Twodeveloped
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subcutaneous
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months
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and NEC1452
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Both
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at mors
three months
injection
(NEC913(NEC913
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PDX models).
Both PDX
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have been
been passaged in 6 generations of mice. (B) Formalin-fixed and paraffin-embedded tumor sections
passaged in 6 generations of mice. (B) Formalin-fixed and paraffin-embedded tumor sections are
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(C) Exome sequencing of NEC913 and NEC1452 PDX tumors demonstrated mutations in
TP53 and RB1.
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Expression of Rb was lost (Figure 2I). Exome sequencing of the NEC913 PDX tumor revealed an RB1 frameshift insertion (1091_1092insCG) leading to a premature stop codon
(Figure 1C, Supplementary Table S1). STR analyses confirmed that the NEC913 patient
blood sample shared the same alleles with the NEC913 PDX tumor (Supplementary Table
S3) and that these samples did not match any of the existing research samples in the
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firmed TP53 stopgain mutations and RB1 frameshift mutation (Figure 1C, Supplementary
Table S2).
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200 μm

3 mm

D)

CgA

E)

SYP

F)

SSTR2

G)

ASCL1

H)

p53

I)

Rb

Figure 2. IHC analyses of NEC913 patient sample: (A) Primary NEC tumor at the ampulla of Vater.
Figure
2. IHC analyses of NEC913 patient sample: (A) Primary NEC tumor at the ampulla of Vater.
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Tumor cells isolated from the cryopreserved NEC913 and NEC1452 tumors yielded
viable cells despite the fact that both patients had been treated with carboplatin/etoposide
chemotherapy, suggesting that these NEC cells are resistant to the treatment. Both sam-

pension cultures or as spheroids embedded in extracellular matrix. By immunofluorescent
staining, we confirmed the expression of CgA and SYP in both cell lines and SSTR2 in only
the NEC913 line (Figure 3A). To further characterize these novel cell lines for additional
neuroendocrine cancer markers, gene expression analyses using quantitative PCR was
performed (Figure 3B–H). In comparison to the established BON cells, NEC913 was found
to have significantly increased SYP and SSTR2 expression (Figure 3B,E). NEC1452 cells 8 of 13
were determined to have increased SSTR1 expression relative to BON cells (Figure 3D).
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Statistical analyses of gene expression changes were performed using T-tests in Prism GraphPad. p
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gene expression changes were performed using T-tests in Prism GraphPad. p < 0.05 was depicted
with *. pTo
< demonstrate
0.01 was depicted
with of
**.NEC PDX models as a potential tool for testing receptorthe utility
targeted theranostics, we conducted a proof-of-concept study whereby we established a
To demonstrate
utility
of NEC PDX
models
a potential
tool and
for testing
receptormouse
model with the
tumor
implantations
using
the as
NEC913
(SSTR2+)
NEC1452
targeted
theranostics,
we conducted
a proof-of-concept
study(Figure
whereby
(SSTR2−)
cells in opposite
shoulders for
SSTR2-targeted imaging
4A).we
Weestablished
then
injectedmodel
these mice
with
a NIR-TOC,
which previously
was
demonstrated
to specifically
a mouse
with
tumor
implantations
using the
NEC913
(SSTR2+)
and NEC1452
detects
on opposite
NEN cells,shoulders
and imaged
using NIR fluorescence
imaging 4A).
[28,30].
(SSTR2
−)SSTR2
cells in
forthem
SSTR2-targeted
imaging (Figure
We then
Imagethese
analysis
that the NIR-fluorescence
signal
localized only
in the
injected
micerevealed
with a NIR-TOC,
which previously
was was
demonstrated
to specifically
deNEC913(SSTR2+)
4B). Tothem
confirm
theNIR
localization
of the imaging
NIR fluorescence
tects
SSTR2 on NENtumor
cells,(Figure
and imaged
using
fluorescence
[28,30]. Image
signal on the NEC tumors, ex vivo NIR fluorescence imaging was performed on both tuanalysis
revealed that the NIR-fluorescence signal was localized only in the NEC913(SSTR2+)
mors after they were removed from the animals. The NIR fluorescence signal was detected

tumor (Figure 4B). To confirm the localization of the NIR fluorescence signal on the NEC
tumors, ex vivo NIR fluorescence imaging was performed on both tumors after they were
removed from the animals. The NIR fluorescence signal was detected in the NEC913
tumor but not NEC1452 (Figure 4C), corroborating the in vivo imaging results (Figure 4B).
Qualitative assessment of SSTR2-mediated uptake was supported by semi-quantitative
image analyses, which revealed an approximately twofold increase and a threefold increase
in fluorescent signal intensity of NEC913 compared to NEC1452 tumors in the in vivo and
ex vivo experiments, respectively (Figure 4D,E).
Further characterization of the NEC913 PDX tumor by IHC showed low expression of
p53, which could be due to the specificity of the antibody for the truncated form of p53,
and no expression of Rb (Figure 5A), which is similar to the expression pattern observed in
original patient tumor IHC analyses (Figure 2H,I). The expression of ASCL1 was lower in
the NEC913 PDX tumor (Figure 5A) when compared to the original tumor (Figure 2G). In
addition, the NEC913 PDX tumor expressed CXCR4 (Figure 5A). The CXCR4 expression
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4. Discussion

GEP NETs and NECs are rare cancers with few in vitro and in vivo models available
for therapeutic testing [31]. GEP NET cell lines and spheroids are difficult to propagate as
they take approximately 2 to 3 weeks to divide [19,22,24,32]. A limited number of GEP
NEC cell and organoid lines have been recently published, but distribution remains lim-
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4. Discussion
GEP NETs and NECs are rare cancers with few in vitro and in vivo models available
for therapeutic testing [31]. GEP NET cell lines and spheroids are difficult to propagate
as they take approximately 2 to 3 weeks to divide [19,22,24,32]. A limited number of
GEP NEC cell and organoid lines have been recently published, but distribution remains
limited. The two currently available human GEP-NEN-derived cell lines, BON and QGP-1,
divide approximately every 3 days and carry TP53 and RB1 mutations [25]. They are
morphologically poorly differentiated, and have Ki-67 rates that exceed 90%, which define
them as NEC cell lines.
Because well-differentiated NETs grow slowly, attempts to propagate them long term
have not generally been successful. We have shown that these can be grown in culture
for up to 9 months, remained well-differentiated, and expressed NET markers such as
synaptophysin, chromogranin, and SSTR2 [19]. However, after about 2 weeks, growth
remains fairly constant at a low level. In this study, we were unsuccessful at establishing all
four frozen NET samples in immunocompromised mice at 3 months post injection (Table 2).
Considering that a majority of GEP NETs are generally slow-growing Grade 2 tumors with
a Ki-67 index less than 20%, it is possible that a period longer than 3 months is required
for tumor formation. Interestingly, even the SBNET sample SBNET1063 (Table 2), which
was a WHO Grade 3 tumor, did not generate a subcutaneous tumor, suggesting that a
xenograft model may not be ideal for NET PDX development. There have been a few NET
cell lines described such as P-STS, GOT1, NT3 [24,25,27], and a well-differentiated PNET
PDX model reported by Chamberlain et al. [33]. Although these appear to be promising
GEP NET models, they have not been widely distributed to many investigators. The most
likely explanation for this is that they cannot be grown in a large enough quantity to share,
or that over time, the cells that do survive could potentially dedifferentiate into NECs.
We established two new NEC cell lines that grow well in culture and can be passaged
through several generations of immunocompromised mice. These lines significantly expand the options for study of NECs and were derived from different sites. The NEC913
was derived from an ampullary NEC and NEC1452 from a retroperitoneal node from a
patient suspected to have a rectal NEC. Both NEC913 and NEC1452 PDX tumors contain
TP53 and RB1 mutations that are commonly reported in GEP NECs [6,34,35]. Both lines
expressed synaptophysin, chromogranin A, and had Ki-67 of >80%. The NEC913 line
expressed SSTR2 and CXCR4 while NEC1452 did not. Tumors from these PDX models
can robustly be passaged in more than six generations of mice with a 100% rate of tumor
formation. NEC cells from both PDX models can be maintained in culture in media supplemented with insulin and nicotinamide as suspension cultures or spheroids embedded in
extracellular matrix.
Several lung NEC lines [36,37] and colon NEC lines such as the HROC47, SS-2, and
NEC-DUE1 and 2 [36,38–40] have been established, but few pancreas and rectal NEC
lines have been reported [39]. Considering the rarity of GEP NEC PDX and cell models,
the NEC913 and NEC1452 PDX models developed in this study could be tremendously
valuable for a variety of pre-clinical experiments. Here, we showed that the NEC913 line
can be useful in confirming the target specificity of NIR-TOC with fluorescence imaging
in a clinically relevant model, suggesting high translational potential (Figure 4). NEC913
PDX model maintains high SSTR2 (Figure 1B) and CXCR4 (Figure 5A,B) expression after
six generations of passages. The NEC913 cells grew as spheroids in suspension culture
or embedded in extracellular matrix, recapitulated characteristics of the PDX tumor, and
stained positive for CXCR4 (Figure 5). This cell line also shows great promise as a potential
tool for future investigations involving PRRT including testing of combination therapies
or highly potent alpha-emitter PRRT [41]. CXCR4 is also emerging as a valuable target in
atypical lung carcinoid and small cell lung cancer, and can be targeted with the radiolabeled
ligand Pentixafor and Pentixather [42,43]. Thus, NEC913 could also serve as an effective
pre-clinical model for PRRT directed at CXCR4. The development and characterization of
these NEC913 and NEC452 PDX lines represent valuable new tools that could overcome
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the significant limitations of existing preclinical models in NEN research and accelerate the
process of drug discovery.
5. Conclusions
Two novel NEC PDX models (NEC913 and NEC1452) were established from cryopreserved patient tumors. Tumors from these PDX models can robustly be passaged in
immunocompromised mice. The NEC913 PDX model maintained SSTR2 expression after
six generations of passages and can be visualized using NIR-TOC peptide. In addition,
the NEC913 PDX model expressed high level of CXCR4, which makes it potentially useful
for CXCR4-targeted theranostics. NEC cells from both PDX models can be maintained
in culture in media supplemented with insulin and nicotinamide. Considering the rarity
of GEP NEC PDX and cell lines, the NEC913 and NEC1452 PDX models are valuable
pre-clinical models for peptide imaging, drug testing experiments, and studying GEP NEC
tumor biology.
Supplementary Materials: The following supporting information can be downloaded at: https://
www.mdpi.com/article/10.3390/cancers14081910/s1, Table S1: List of curated mutations identified
in NEC913 PDX tumors by exome sequencing. Table S2: List of curated mutations identified in
NEC1452 PDX tumors by exome sequencing. Table S3: Short Tandem Repeats analyses of NEC913
PDX tumors and patient periphery blood mononuclear cells. Table S4: Short Tandem Repeats analyses
of NEC1452 PDX tumors.
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